Evidence map›Paper›PMID 35262728›Full record

ArticleThe Journal of infectious diseases2022

Codelivery of Antigens and Adjuvant in Polymeric Nanoparticles Coated With Native Parasite Membranes Induces Protective Mucosal Immunity Against Giardia lamblia.

Jiarong Zhou, Yukiko Miyamoto, Sozaburo Ihara, Ashley V Kroll, Noelle Nieskens, Vivien N Tran, Elaine M Hanson, Ronnie H Fang, Liangfang Zhang, Lars Eckmann

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Extracellular Vesicles ofJournal of extracellular biology · 2026
    Article
  3. Harnessing Nanocarriers to Advance Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Jiarong ZhouDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, California, USA.
Yukiko MiyamotoDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Sozaburo IharaDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Ashley V KrollDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, California, USA.
Noelle NieskensDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Vivien N TranDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Elaine M HansonDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Ronnie H FangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, California, USA.
Liangfang ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, California, USA.
Lars EckmannDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
University of California, San Diego · US

Funding

San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8M
Membrane-cloaked nanoparticles as mucosal vaccines against giardiasisR21AI166815 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, ZHANG, LIANGFANG · 2021 to 2022
$435k
NIAID NIH HHS R21 AI166815NIDDK NIH HHS P30 DK120515NIH HHS AI166815
6 · The paper itself

Abstract

The protozoan pathogen Giardia lamblia is an important worldwide cause of diarrheal disease and malabsorption. Infection is managed with antimicrobials, although drug resistance and treatment failures are a clinical challenge. Prior infection provides significant protection, yet a human vaccine has not been realized. Individual antigens can elicit partial protection in experimental models, but protection is weaker than after prior infection. Here, we developed a multivalent nanovaccine by coating membranes derived from the parasite onto uniform and stable polymeric nanoparticles loaded with a mucosal adjuvant. Intranasal immunization with the nanovaccine induced adaptive immunity and effectively protected mice from G. lamblia infection.

Indexed as

Giardia lambliaGiardiasisNanoparticlesParasitesAdjuvants, ImmunologicAnimalsHumansImmunity, MucosalMiceAdjuvants, Immunologicbiomimetic nanoparticlegiardiasisintestinal mucosamultivalent vaccinenanovaccineprotozoa

Identifiers

PMID35262728
PMCPMC9400425
OpenAlexW4220746687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.